Obesity, inflammation and insulin resistance: Which role for adipokines?;Obésité, inflammation et insulinorésistance: Quel rôle pour les adipokines?

Therapie

Volumn 62, Issue 4, 2007, Pages 285-292

  Antuna Puente, Barbara ^a,b   Feve, Bruno ^a   Fellahi, Soraya ^b   Bastard, Jean Philippe ^b  

^a INSERM   (France)

^b HÔPITAL TENON   (France)

Author keywords

Adipocyte; Adipokines; Diabetes; Macrophage; Obesity

Indexed keywords

ADIPOCYTOKINE;

ADIPOCYTE MEMBRANE; ADIPOSE TISSUE; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; HUMAN; INFLAMMATORY DISEASE; INSULIN RESISTANCE; MACROPHAGE MIGRATION; OBESITY; PRIORITY JOURNAL; PROTEIN SECRETION; PROTEIN SYNTHESIS; ADIPOCYTE; ANIMAL; INFLAMMATION; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ADIPOCYTES; ADIPOKINES; ADIPOSE TISSUE; ANIMALS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; NEUTROPHIL INFILTRATION; OBESITY;

EID: 38449114417     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2007055     Document Type: Conference Paper

References (77)

1. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347-55
2. Zhang Y, Proenca R, Maffei M, et al. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32
3. Ahima RS, Flier JS. Leptin. Annu Rev Physiol 2000; 62: 413-37
4. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-5
5. Vidal H, Auboeuf D, De Vos P, et al. The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. J Clin Invest 1996; 98: 251-5
6. Lefebvre AM, Laville M, Vega N, et al. Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998; 47: 98-103
7. Loffreda S, Yang SQ, Lin HZ, et al. Leptin regulates proinflammatory immune responses. FASEB J 1998; 12: 57-65
8. van Dielen FM, van't Veer C, Schols AM, et al. Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals. Int J Obes Relat Metab Disord 2001; 25: 1759-66
9. Cooke JP, Oka RK. Does leptin cause vascular disease? Circulation 2002; 106: 1904-5
10. Konstantidines S, Schafer K, Koschnick S, et al. leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism of atherothrombotic disease in obesity. J Clin Invest 2001; 108: 1533-40
11. Yamagishi SI, Edelstein D, Du XL, et al. Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A. J Biol Chem 2001; 276: 25096-100
12. O'Rourke LM, Gronning SJ, Yeaman PR, et al. Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin. J Biol Chem 2002; 277: 42557-62
13. Sierra-Honnigmann MR, Nath AK, Murakami C, et al. Biological action of leptin as an angiogenic factor. Science 1998; 281: 1683-6
14. Kadowaki T, Yamauchi T. Adiponectin and Adiponectin Receptors. Endocr Rev 2005; 26: 439-51
15. Lihn AS, Bruun JM, He G, et al. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol 2004; 219: 9-15
16. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidaion by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288-95
17. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6
18. Ouchi N, Kihara S, Arita Y, et al. Matsuzawa, adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103: 1057-63
19. Arita Y, Kihara S, Ouchi N, et al. Adipocyte-derived plasma protein adiponectin acts as a platelet-derived growth factor-BB-binding protein and regulates growth factor-induced common postreceptor signal in vascular smooth muscle cell. Circulation 2002; 105: 2893-8
20. Ouchi N, Kihara S, Arita Y, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signalling through a camp-dependent pathway. Circulation 2000; 102: 1296-301
21. Bruun JM, Lihn AS, Verdich C, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab 2003; 285: E527-33
22. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003; 423: 762-9
23. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91
24. Koistinen HA, Bastard JP, Dusserre E, et al. Subcutaneous adipose tissue expression of tumour necrosis factor-alpha is not associated with whole body insulin resistance in obese nondiabetic or in type-2 diabetic subjects. Eur J Clin Invest 2000; 30: 302-10
25. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 1997; 82: 4196-200
26. Ouchi N, Kihara S, Arita Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999; 100: 2473-6
27. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042-7
28. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. Am J Physiol Heart Circ Physiol 1994; 266: H2535-41
29. Choy JC, Granville DJ, Hunt DW, et al. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 2001; 33: 1673-90
30. Hermann C, Assmus B, Urbich C, et al. Insulin-mediated stimulation of protein kinase Akt: a potent survival signalling cascade for endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 402-9
31. Fried SK, Bunkin DA, Greenberg AS, et al. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998; 83: 847-50
32. Bastard JP, Maachi M, Tran Van Nhieu J, et al. Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 2002; 87: 2084-9
33. Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273-82
34. Maachi M, Piéroni L, Bruckert E, et al. Systemic low grade inflammation is related to both circulating and adipose tissue TNFα, leptin and IL-6 levels in obese women. Int J Obes 2004; 28: 993-7
35. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 2003; 107: 363-9
36. Yudkin JS, Kumari M, Humphries SE, et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000; 148: 209-14
37. Bastard JP, Jardel C, Bruckert E, et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab 2000; 85: 3338-42
38. Ihle JN, Witthuhn BA, Quelle FW, et al. Silvennoinen, Signaling through the hematopoietic cytokine receptors. Annu Rev Immunol 1995; 13: 369-98
39. Kroder G, Bossenmaier B, Kellerer M, et al. Tumor necrosis factor-alpha-and hyperglycemia-induced insulin resistance. Evidence for different mechanisms and different effects on insulin signalling. J Clin Invest 1996; 97: 1471-7
40. Mooney RA, Senn J, Cameron S, et al. Suppressors of cytokine signaling-1 and -6 associate with and inhibit the insulin receptor. A potential mechanism for cytokine-mediated insulin resistance. J Biol Chem 2001; 276: 25889-93
41. Lagathu C, Bastard JP, Auclair M, et al. Chronic Interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Com 2003; 311: 372-9
42. Rieusset J, Bouzakri K, Chevillotte E, et al. SOCS (suppressor of cytokine signaling)-3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 2004; 53: 2232-41
43. Kim KH, Lee K, Moon YS, et al. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 2001; 276: 11252-6
44. Banerjee RR, Rangwala SM, Shapiro JS, et al. Regulation of fasted blood glucose by resistin. Science 2004; 303: 1195-8
45. Verma S, Li SH, Wang CH, et al. Resistin promotes endothelial activation: further evidence of adipokine-endothelial interaction. Circulation 2003; 108: 736-40
46. Calabro P, Samudio I, Willerson JT, et al. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004; 110: 3335-40
47. Jackson MB, Osei SY, Anima RS. The endocrine role of adipose tissue: focus on adiponectin and resistin. Cur Opin Endocrinol Diab 2005; 12: 163-70
48. Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary heart disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 2004; 109: 726-32
49. Leinonen E, Hurt-Camejo E, Wiklund O, et al. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003; 166: 387-94
50. Lin Y, Rajala MW, Berger JP, et al. Hyperglycemia-induced production of acute phase reactants in adipose tissue. J Biol Chem 2001; 276: 42077-83
51. Juan-Vague I, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulinresistance and atherothrombosis. Diabetologia 1991; 34: 457-62
52. Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: 2273-82
53. Bastard JP, Pieroni L, Hainque B. Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diabetes Metab Res Rev 2000; 16: 192-201
54. Montague CT, Prins JB, Sanders L, et al. Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 1998; 47: 1384-91
55. Alessi MC, Peiretti F, Morange P, et al. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-7
56. Eriksson P, Van Harmelen V, Hoffstedt J. Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb Haemost 2000; 83: 545-8
57. Ma LJ, Mao SL, Taylor KL, et al. Prevention of obesity and insulinresistance in mice lacking plasminogen activator inhibitor-1. Diabetes 2004; 53: 336-46
58. Alessi MC, Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler Thromb Vasc Biol 2006; 26: 2200-7
59. Dusserre E, Moulin P, Vidal H. Differences in mRNA expression of tumor necrosis factor alpha is not associated with whole body insulin resistance in obese nondiabetic or type 2 diabetic subjects. Eur J Clin Invest 1997; 82: 4196-200
60. Van Harmelen V, Ariapart P, Hoffstedt J, et al. Increased adipose angiotensinogen gene expression in human adiposity. Obes Res 2000; 8: 337-41
61. Massiera F, Bloch-Faure M, Cellier D. Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. FASB J 2001; 5: 2727-9
62. Clement K, Viguerie N, Poitou C, et al. Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects. FASEB J 2004; 18: 1657-69
63. Cancello R, Henegar C, Viguerie N, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 2005; 54: 2277-86
64. Xu H, Barnes GT, Yang Q, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003; 112: 1821-30
65. Charriere G, Cousin B, Arnaud E, et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem 2003; 278: 9850-5
66. Cousin B, Andre M, Villena P, et al. Human adipose cells as candidates in defense and tissue remodeling phenomena, Biochem Biophys Res Commun. 2003; 309: 502-5
67. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112: 1796-808
68. Curat CA, Miranville A, Sengenes C, et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 2004; 53: 1285-92
69. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117: 175-84
70. Yuan M, Konstantopoulos N, Lee J, et al. Shoelson, reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk-beta. Science 2001; 293: 1673-7
71. Kim JK, Kim YJ, Fillmore JJ, et al. Prevention of fat-induced insulin resistance by salicylate. J Clin Invest 2001; 108: 437-46
72. Cai D, Yuan M, Frantz DF, et al. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 2005; 11: 183-90
73. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6
74. Nakatani Y, Kaneto H, Kawamori D, et al. Modulation of the JNK pathway in liver affects insulin resistance status. J Biol Chem 2004; 279: 45803-9
75. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 1998; 396: 77-80
76. Gao Z, Zuberi A, Quon MJ, et al. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. J Biol Chem 2003; 278: 24944-50
77. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002; 109: 1321-6